Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
=====================================================================================================================================================================

* Jinyu Zhang
* Pablo Saenz-lopez Larrocha
* Bin Zhang
* Derek Wainwright
* Payal Dhar
* Jennifer D. Wu